Ataxic Disorders¶
Chapter 450 | Part 13: Neurologic Disorders
KEY CLINICAL POINTS¶
- Ataxia is a clinical syndrome characterized by impaired coordination of movement, with causes ranging from genetic disorders to metabolic, infectious, and toxic etiologies.
- Genetic ataxias (e.g., spinocerebellar ataxias [SCAs]) are caused by CAG/CTG repeat expansions in specific genes, leading to polyglutamine-mediated neurodegeneration.
- Diagnostic differentiation between cerebellar ataxia and vestibular/other causes is critical, using clinical patterns, imaging, and genetic testing.
- Management depends on etiology: treatable causes (e.g., hypothyroidism, infections) require prompt intervention; genetic ataxias may benefit from supportive care and emerging therapies like antisense oligonucleotides.
- Imaging (MRI) and cerebrospinal fluid (CSF) analysis are essential for identifying structural lesions, infections, or inflammatory processes.
1. DEFINITION & OVERVIEW¶
Ataxia refers to impaired coordination of movement, typically due to cerebellar dysfunction. It may present as symmetric, progressive (e.g., inherited ataxias) or focal, unilateral (e.g., tumors, infections). Key features include gait instability, dysarthria, nystagmus, and scanning speech. Differentiation from vestibular or sensory ataxia is critical for diagnosis.
Table 450-1: Etiology of Cerebellar Ataxia¶
| Symmetric/Progressive Signs | Focal/Ipsilateral Cerebellar Signs |
|---|---|
| Acute (hours-days): Alcohol, lithium, phenytoin, barbiturates | Acute (hours-days): Mercury, solvents, gasoline, glue |
| Subacute (days-weeks): Acute viral cerebellitis | Cytotoxic chemotherapeutic drugs |
| Chronic (months-years): Postinfection syndrome, hypothyroidism | Antigliadin antibody syndrome |
| Subacute (days-weeks): Intoxication, Lyme disease | Vascular: cerebellar infarction, hemorrhage |
| Chronic (months-years): Multiple sclerosis, congenital lesions | Infectious: cerebellar abscess (MRI/CT) |
1.1 Classification by Etiology¶
Ataxia is classified into: 1. Genetic/Inherited: Spinocerebellar ataxias (SCAs), Friedreich’s ataxia, etc. 2. Acquired: Toxic (alcohol, drugs), metabolic (hypothyroidism), infectious (syphilis, Lyme), autoimmune (paraneoplastic), or structural (tumors, stroke).
1.2 Diagnostic Approach¶
Key steps include: - Assessing gait, speech, and eye movements - Identifying focal vs. symmetric patterns - Evaluating for red flags (e.g., fever, weight loss, family history) - Ordering MRI, CSF analysis, and genetic testing based on clinical suspicion.
2. EPIDEMIOLOGY¶
Genetic ataxias account for ~50% of cases. Friedreich’s ataxia is the most common inherited form, affecting ~1 in 50,000. Sporadic ataxias (e.g., paraneoplastic, toxic) are more common in adults. Risk factors include alcohol abuse, autoimmune disorders, and inherited mutations in genes like PRNP, ATXN1, or FXN.
2.1 Demographics¶
Friedreich’s ataxia typically presents before age 25; MJD (SCA3) peaks in 20s-30s. Paraneoplastic ataxia is more common in women and associated with cancers like breast, ovarian, or small-cell lung cancer.
3. ETIOLOGY & PATHOPHYSIOLOGY¶
Genetic ataxias are caused by CAG/CTG repeat expansions in genes like ATXN1 (SCA1), ATXN2 (SCA2), ATXN3 (MJD/SCA3), and ATXN7 (SCA7). These expansions lead to polyglutamine aggregates, neuronal dysfunction, and progressive degeneration. Toxic causes include alcohol, drugs (phenytoin, lithium), and heavy metals. Infections (e.g., syphilis, Lyme) or autoimmune processes (e.g., paraneoplastic) may also cause ataxia.
3.1 Molecular Mechanisms¶
Expanded CAG repeats produce polyglutamine proteins (e.g., ataxin-1, -3) that disrupt transcription, cause protein aggregation, and trigger neuronal apoptosis. Mitochondrial dysfunction (e.g., in Friedreich’s ataxia) leads to iron overload and oxidative stress.
4. CLINICAL FEATURES¶
Symptoms vary by etiology: - Symmetric progressive ataxia: Gait instability, dysarthria, scanning speech, nystagmus. - Focal ataxia: Ipsilateral cerebellar signs (e.g., dysmetria, dysdiadochokinesia) with associated cranial nerve palsies or mass lesions. - Acute ataxia: Sudden onset from toxins, stroke, or infections (e.g., viral encephalitis).
4.1 Specific Syndromes¶
SCA1: Cerebellar atrophy, extrapyramidal features, dementia. MJD (SCA3): Spasticity, dystonia, ophthalmoparesis. Friedreich’s ataxia: Sensory neuropathy, cardiomyopathy, vitamin E deficiency.
5. DIFFERENTIAL DIAGNOSIS¶
Distinguish between: - Cerebellar vs. vestibular ataxia (lack of vertigo in cerebellar causes) - Sensory ataxia (worsens with eyes closed) - Paraneoplastic syndromes (e.g., anti-Yo antibodies) - Toxic/metabolic causes (e.g., alcohol, hypothyroidism) - Structural lesions (e.g., tumors, stroke).
5.1 Red Flags¶
Fever, weight loss, recent infection, family history of ataxia, or autoimmune markers (e.g., anti-Yo, anti-Ri) suggest paraneoplastic or autoimmune etiologies.
6. INVESTIGATIONS & DIAGNOSIS¶
Diagnostic workup includes: - MRI: Detect cerebellar atrophy, tumors, or demyelination. - CSF: Rule out infections (e.g., syphilis, Lyme) or inflammatory processes. - Genetic testing: For SCAs, Friedreich’s ataxia, or mitochondrial disorders. - Autoantibody panels: For paraneoplastic syndromes (e.g., anti-Yo, anti-Ri). - Laboratory tests: Thyroid function, vitamin levels (B12, E), and heavy metal screening.
6.1 Diagnostic Algorithms¶
- Assess gait, speech, and eye movements.
- Order MRI and CSF analysis.
- Test for autoimmune antibodies (e.g., anti-Yo, anti-Ri) and paraneoplastic syndromes.
- Perform genetic testing for SCAs or Friedreich’s ataxia.
- Evaluate for metabolic/toxic causes (e.g., alcohol, hypothyroidism).
7. MANAGEMENT & TREATMENT¶
Treatment is etiology-driven: - Toxic/metabolic: Discontinue causative agents, correct deficiencies (e.g., vitamin B12, E), and manage hypothyroidism. - Infectious: Antibiotics for bacterial abscesses, antiparasitics for Lyme disease. - Paraneoplastic: Remove tumor, immunotherapy, or corticosteroids. - Genetic ataxias: Supportive care, 4-aminopyridine for SCA27B, and emerging therapies (e.g., antisense oligonucleotides).
7.1 Pharmacologic Therapies¶
Acetazolamide for episodic ataxia (EA), 4-aminopyridine for SCA27B, and antioxidants for mitochondrial ataxias. Avoid phenytoin and alcohol in cerebellar ataxia.
8. PROGNOSIS & COMPLICATIONS¶
Prognosis varies: - Friedreich’s ataxia: Progressive disability, cardiac involvement, and early mortality (mean age 35). - MJD (SCA3): Rapid progression leading to death within 15 years of onset. - Paraneoplastic ataxia: Variable, with potential remission after tumor removal. - Toxic causes: Reversible with prompt intervention.
8.1 Complications¶
Cardiomyopathy (Friedreich’s), respiratory failure (MJD), and secondary infections in immunocompromised patients. Long-term complications include mobility impairment and dementia.
9. SPECIAL CONSIDERATIONS¶
Pregnancy: Genetic counseling for inherited ataxias. Pediatrics: Early detection of Friedreich’s ataxia. Elderly: Consider drug-induced ataxia or stroke. Special populations: Mitochondrial disorders (e.g., SCA27B) require dietary management.
9.1 Genetic Counseling¶
Counsel families for autosomal dominant (SCAs), recessive (Friedreich’s), or mitochondrial ataxias. Note anticipation in SCA1 and MJD.
10. KEY POINTS & CLINICAL PEARLS¶
- Symmetric, progressive ataxia suggests genetic or metabolic causes; focal ataxia points to structural/acute etiologies.
- MRI and CSF analysis are critical for diagnosing structural lesions, infections, or inflammatory processes.
- Genetic testing is essential for SCAs and Friedreich’s ataxia.
- Avoid alcohol and phenytoin in cerebellar ataxia.
- Early treatment of paraneoplastic syndromes (e.g., tumor removal) can reverse ataxia.